Selpercatinib Regimen

**Semantic type:** Therapeutic or Preventive Procedure

**Definition:** A regimen consisting of selpercatinib that may be used in the treatment of ampullary, appendiceal, pancreatic, and small bowel adenocarcinomas, breast, biliary tract, cervical, colorectal, and esophageal and esophagogastric junction cancers, hepatocellular carcinoma, gastric, ovarian, fallopian tube, and primary peritoneal, vaginal, and occult primary cancers, anaplastic carcinoma, follicular carcinoma, Hurthle cell carcinoma, medullary carcinoma, non-small cell lung cancer (NSCLC), papillary carcinoma, salivary gland tumors, extrapulmonary poorly differentiated neuroendocrine carcinoma/large or small cell carcinoma/mixed neuroendocrine-non-neuroendocrine neoplasm, soft tissue sarcoma, uterine sarcoma, and certain histiocytic neoplasms, such as Langerhans cell histiocytosis, Erdheim-Chester disease and Rosai-Dorfman disease.

**Synonyms:** - Retevmo Regimen - Selpercatinib monotherapy